Cargando…
Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis
Introduction. Low molecular weight heparin (LMWH) is preferred for malignancy-associated venous thromboembolism (VTE). Many providers monitor LMWH with anti-Xa levels, despite little validation on correspondence with patient outcome. Methods. This is a retrospective, single institution study of anti...
Autores principales: | Yentz, Sarah, Onwuemene, Oluwatoyosi A., Stein, Brady L., Cull, Elizabeth H., McMahon, Brandon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620379/ https://www.ncbi.nlm.nih.gov/pubmed/26543644 http://dx.doi.org/10.1155/2015/126975 |
Ejemplares similares
-
Clinical Scenarios for Discordant Anti-Xa
por: Vera-Aguilera, Jesus, et al.
Publicado: (2016) -
Bleeding is associated with intravenous immunoglobulin and therapeutic plasma exchange use in heparin‐induced thrombocytopenia: A propensity matched analysis
por: Soares Ferreira Júnior, Alexandre, et al.
Publicado: (2021) -
Apixaban anti-Xa level monitoring in treatment of acute upper extremity deep vein thrombosis for patient on chronic hemodialysis: a case report
por: Roberge, Guillaume, et al.
Publicado: (2021) -
Anti-factor Xa Monitoring and Activated Charcoal for a Pediatric Patient With Rivaroxaban Overdose
por: Carr, Brendan M., et al.
Publicado: (2018) -
Personalized prophylactic anticoagulation in hospitalized patients with Covid-19 – The role of anti-Xa monitoring
por: Kofteridis, Diamantis P., et al.
Publicado: (2021)